Global Oncology

Frontline dostarlimab plus chemotherapy has been approved in the EU for all adult patients with primary advanced or recurrent endometrial cancer.

Senaparib has received marketing authorization in China as a first-line maintenance therapy for advanced ovarian cancer.

Limertinib was approved in China for locally advanced or metastatic non–small cell lung cancer harboring an EGFR T790M mutation.

First-line nivolumab plus chemotherapy numerically improved survival vs chemotherapy alone in Asian patients with unresectable/metastatic urothelial cancer.

Jun-Jie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer.

Savolitinib has received full NMPA approval for locally advanced/metastatic non–small cell lung cancer with MET exon 14 skipping alterations.

Adjuvant nivolumab plus chemoradiotherapy improved disease-free survival in resected, locally advanced head and neck squamous cell carcinoma.

China’s NMPA has approved isatuximab plus pomalidomide and dexamethasone in adult patients with pretreated multiple myeloma.

Enfortumab vedotin-efjv plus has received NMPA approval for patients with locally advanced or metastatic urothelial cancer.

A marketing authorization application has been submitted to the EMA seeking the approval of eflornithine for patients with high-risk neuroblastoma.

China’s NMPA has approved zolbetuximab plus chemotherapy for CLDN18.2-positive advanced gastric or GEJ adenocarcinoma.

Tarlatamab was granted conditional marketing authorization in the United Kingdom for previously treated extensive-stage small cell lung cancer.

China's NMPA has approved taletrectinib adipate capsule for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC.

China’s NMPA has granted priority review to the NDA for savolitinib plus osimertinib in pretreated EGFR-mutated advanced NSCLC with MET amplification.

The European Commission has approved a type II variation extended indication for lazertinib plus amivantamab in frontline EGFR-mutated NSCLC.

Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.

European approval is no longer being sought for Dato-DXd in advanced nonsquamous non–small cell lung cancer.

Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.

The FDA awards accelerated approval to encorafenib regimen in BRAF V600E+ CRC, ensartinib wins approval in ALK+ non–small cell lung cancer, and more.

China's NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer after a previous ROS1 TKI.

Uproleselan plus chemotherapy did not improved overall survival in relapsed/refractory acute myeloid leukemia.

Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL.

The EMA’s CHMP has recommended the approval of an expanded indication for dostarlimab plus chemotherapy in primary advanced/recurrent endometrial cancer.

The EMA’s CHMP has recommended the approval of imetelstat for transfusion-dependent anemia in lower-risk myelodysplastic syndrome.

Savolitinib plus osimertinib received breakthrough therapy designation in China for pretreated, locally advanced or metastatic EGFR-positive NSCLC with MET amplification.